Bringing the fundamentals into focus…
Back to Phathom Pharmaceuticals, Inc.
How Phathom Pharmaceuticals, Inc. stacks up
PHAT · against 440 other Healthcare companies of similar size
Valuation
75/ 100
Above the middle of the pack.
Ranked #118 of 441 · scores higher than 73% of peers
Bars: peers in each 10-point band of the valuation score40 peers with a valuation score of 70–79, including PHAT · Click a bar to see the companies
Why valuation scores 75?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- lower earnings for the price paid: weaker than 89% of peers. Earnings yield: 26.3% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -8.3% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -7.9% vs peer median 0.0%
Metric by metric
Position: dot = PHAT, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | PHAT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 428 reported | -22.0% | 0.4% | 14% | 30% | |
| EBITDA yieldHigher is better · 446 reported | -4.8% | 3.3% | 26% | 50% | |
| Free cash flow yieldHigher is better · 204 reported | -7.9% | -7.3% | 47% | 20% | |
| Book yieldHigher is better · 438 reported | -74.9% | 49.0% | 1% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around PHATScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score